- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05548062
Badanie mające na celu identyfikację i opisanie czynników predykcyjnych zdarzeń zakrzepowo-zatorowych u pacjentów z czerwienicą prawdziwą wysokiego ryzyka (Prospero)
Prospektywne badanie obserwacyjne mające na celu identyfikację i opisanie czynników predykcyjnych zdarzeń zakrzepowo-zatorowych u pacjentów z czerwienicą prawdziwą wysokiego ryzyka
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.
This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
All patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. In addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. According to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of TEs) and are considered current clinical practice. Data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise.
Patients in both cohorts will be followed for 3 years after enrollment and will have visits at Months 6, 12, 18, 24, 30 and 36. A time window of ± 1 month is permitted for all visits.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Naples, Włochy, 80131
- Novartis Investigative Site
-
-
AL
-
Alessandria, AL, Włochy, 15121
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Włochy, 60020
- Novartis Investigative Site
-
-
BA
-
Bari, BA, Włochy, 70124
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Włochy, 40138
- Novartis Investigative Site
-
-
CO
-
Como, CO, Włochy, 22100
- Novartis Investigative Site
-
-
CS
-
Cosenza, CS, Włochy, 87100
- Novartis Investigative Site
-
-
CT
-
Catania, CT, Włochy, 95123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Włochy, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Włochy, 16132
- Novartis Investigative Site
-
-
LE
-
Lecce, LE, Włochy, 73100
- Novartis Investigative Site
-
Tricase, LE, Włochy, 73039
- Novartis Investigative Site
-
-
MB
-
Monza, MB, Włochy, 20900
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Włochy, 20122
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Włochy, 90127
- Novartis Investigative Site
-
Palermo, PA, Włochy, 90146
- Novartis Investigative Site
-
-
PC
-
Piacenza, PC, Włochy, 29121
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Włochy, 35128
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Włochy, 56126
- Novartis Investigative Site
-
-
PR
-
Parma, PR, Włochy, 43126
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria, RC, Włochy, 89124
- Novartis Investigative Site
-
-
RE
-
Reggio Emilia, RE, Włochy, 42123
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Włochy, 00168
- Novartis Investigative Site
-
Roma, RM, Włochy, 00161
- Novartis Investigative Site
-
Roma, RM, Włochy, 00189
- Novartis Investigative Site
-
-
SA
-
Pagani, SA, Włochy, 84016
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Włochy, 10043
- Novartis Investigative Site
-
Torino, TO, Włochy, 10126
- Novartis Investigative Site
-
-
TR
-
Terni, TR, Włochy, 05100
- Novartis Investigative Site
-
-
VA
-
Varese, VA, Włochy, 21100
- Novartis Investigative Site
-
-
VI
-
Vicenza, VI, Włochy, 36100
- Novartis Investigative Site
-
-
VR
-
Verona, VR, Włochy, 37134
- Novartis Investigative Site
-
-
VT
-
Viterbo, VT, Włochy, 01033
- Novartis Investigative Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
The study will involve patients in Italy with high-risk Polycythemia Vera
Opis
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Age ≥18 years.
- Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification.
- At least one TE after diagnosis or up to 2 years prior to diagnosis.
- Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Hydroxyurea
Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance. |
Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study. |
|
Ruxolitinib
Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment. |
Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of abnormalities presented in patients with Thromboembolic Events (TEs) during the follow up
Ramy czasowe: Up to 36 months
|
Demographics, blood pressure, laboratory blood tests, and use of antiplatelets and/or anticoagulants are predictors of TE occurrence, a univariate Cox regression model for repeated events will be applied for each predictor considering all the TEs occurring within 12 months and the time from baseline to each occurrence. Predictors found statistically significant at the 5% level will then be considered in a multivariate Cox regression model for repeated events. |
Up to 36 months
|
|
Blood pressure
Ramy czasowe: Up to month 36
|
Blood pressure is going to be collected |
Up to month 36
|
|
Number of patients with abnormal Body Mass Index (BMI)
Ramy czasowe: Up to month 36
|
Number of patients with abnormal Body Mass Index (BMI) will be collected |
Up to month 36
|
|
Number of patients with abnormal weight
Ramy czasowe: Up to month 36
|
Number of patients with abnormal weight will be collected |
Up to month 36
|
|
Number of patients with abnormal Neutrophil (NEP) count
Ramy czasowe: Up to 36 months
|
Number of patients with abnormal Neutrophil (NEP) count will be collected |
Up to 36 months
|
|
Number of patients with abnormal White blood Count (WBC)
Ramy czasowe: Up to 36 months
|
Number of patients with abnormal White blood Count (WBC) will be collected |
Up to 36 months
|
|
Number of patients with abnormal Lymphocytes (LYP) count
Ramy czasowe: Up to 36 months
|
Number of patients with abnormal Lymphocytes (LYP) count will be collected |
Up to 36 months
|
|
Number of participants using antiplatelets and/or anticoagulants on the incidence of TEs
Ramy czasowe: Up to 36 months
|
Number of participants using antiplatelets and/or anticoagulants on the incidence of Thromboembolic Events (TEs) will be collected |
Up to 36 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Synergistic combinations of predictive factors
Ramy czasowe: Up to 36 months
|
Synergistic combinations of predictive factors (Red cell Distribution Width, neutrophils, lymphocytes, neutrophil/ lymphocyte ratio and platelets). Synergy score is defined as the product of the individual significances of variable 1 and 2 (expected) divided by the significance of the two-variable model (observed) To investigate cases of extreme synergy, instances in which two variables split the given cohort into high-risk and low-risk patients are far better than either variable alone. A simple synergy scoring metric to rank variable in terms of synergy (S):S12=(P1*P2)/P12 where P1 and P2 are the maximum possible (Cox regression derived) p-values for variable 1 and variable 2 and P12 was the max. p-value possible from the combination of variables 1 and 1. This synergy is intended to capture a variable that may provide exclusive non-redundant information when attempting to split a cohort based on risk and may provide an added insight into the functional/clinical rationale of a model |
Up to 36 months
|
|
Yearly incidence of TEs
Ramy czasowe: 36 months
|
Yearly incidence of Thromboembolic Events (TEs) will be collected |
36 months
|
|
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts
Ramy czasowe: 36 months
|
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts will be collected |
36 months
|
|
Incidence and severity of adverse events
Ramy czasowe: 36 months
|
Incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
36 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CINC424BIT01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .